News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Key Points Interested in Intermap Technologies Co.? Here are five stocks we like better. Second-quarter results weakened as delayed Indonesian government contract awards eliminated acquisition-services revenue. Revenue fell to CAD 2 million from CAD 3 million, while the net loss widened to CAD 2.1 …
Dermata Therapeutics Inc. (NASDAQ: DRMA) stock surged 27.78% pre-market after the company reported its second-quarter results. Despite missing analyst estimates for earnings per share, the company is preparing to launch its first commercial skincare product, Tome Foundational Treatment, on August 25. Dermata Therapeutics aims …
This article provides a detailed overview of Dermata Therapeutics Inc (DRMA) stock performance, financial data, and analyst ratings. It highlights the company's focus on medical dermatology and its two main product candidates, XYNGARI and DMT410, which utilize Spongilla technology for various skin conditions. The …
Perma-Fix Environmental Services Inc (PESI) discussed its Q2 2026 earnings, highlighting a significant $4.4 billion master IDIQ subcontract for the Hanford tank waste grouting program and a 29% growth in treatment backlog. Despite a revenue shortfall and net loss in Q2 due to customer-directed …
Certain Warrants of Perma-Fix Environmental Services, Inc. (PESI) are currently under a 91-day lock-up agreement. This lock-up started on May 14, 2026, and will conclude on August 13, 2026. During this period, company directors and executive officers are restricted from selling or transferring common …
Perma-Fix Environmental Services, Inc. reported its second quarter 2026 financial results, which did not meet expectations but included significant operational milestones. The company announced the award of a Master IDIQ Subcontract for waste treatment at the Hanford Site, with task orders potentially starting in …
This article analyzes Perma-pipe International Holdings Inc. (NASDAQ: PPIH) with a focus on disciplinary and rules-based execution. It highlights a strong near-term sentiment with a neutral mid and long-term outlook, identifying an exceptional 62.6:1 risk-reward setup. The analysis provides specific institutional trading strategies, including …
Dermata Therapeutics (DRMA) stock is gaining attention due to its strategic pivot from prescription dermatology to direct-to-consumer skincare with the upcoming launch of Tome Foundational Treatment on August 25, 2026. This move aims to establish a recurring revenue stream, shifting the company's business model. …
Dermata Therapeutics (DRMA) stock is seeing increased trading activity and positive sentiment due to its strategic pivot towards a direct-to-consumer skincare market. The company is set to launch "Tome Foundational Treatment," its first skincare product utilizing Bioneedle technology, on August 25, 2026. This move …
Perma-Fix Environmental Services stock slipped 0.8% in after-hours trading after the company announced a Q2 2026 net loss of approximately $6.0 million on revenues of $13 million. The decline is attributed to delayed waste treatment, project delays, higher costs, an upcoming lock-up expiry for …
Perma-Fix Environmental Services (PESI) has been awarded a master IDIQ subcontract by Hanford Tank Waste Operations & Closure. This subcontract is for the treatment and disposal of pretreated liquid mixed low-level waste from the U.S. Department of Energy's Hanford nuclear site and has a …
Perma-Fix Environmental Services (PESI) has been awarded a Master Indefinite Delivery/Indefinite Quantity (IDIQ) Subcontract by Hanford Tank Waste Operations & Closure (H2C) for the treatment and disposal of mixed low-level waste from the U.S. Department of Energy’s Hanford Site. The subcontract, effective August 11, …
(RTTNews) - Dermata Therapeutics, Inc. (DRMA) announced financial results for the second quarter ended June 30, 2026, alongside a corporate update highlighting its transition into a commercial-stage skincare company. The San Diego-based firm is preparing to launch its first direct-to-consumer product, Tome Foundational Treatment, …
This article provides a price-driven analysis of Neuberger Berman Next Generation Connectivity Fund Inc. (NASDAQ: NBXG) for rule-based strategies. It highlights a near-term strong sentiment with a mid-channel oscillation pattern, offering a significant risk-reward setup. The analysis includes AI-generated institutional trading strategies tailored for …
DERMATA THERAPEUTICS ($DRMA) released its Q2 2026 earnings, reporting -$0.74 per share, missing estimates by $0.18, with revenue matching expectations at $0. Despite missing earnings estimates, the stock price rose by 43.66% since market close. The article also details recent insider trading activity, including …
Dermata Therapeutics (DRMA) experienced a significant post-market surge of 35.18%. This jump follows the company's announcement of positive topline data from its Phase 2b trial for DMT310 in treating moderate-to-severe rosacea. The results showed statistically significant improvements in inflammatory lesion count, erythema, and Global …
This article details the performance of 12 health care stocks during Tuesday's after-market session, highlighting both gainers and losers. Several companies, including Dermata Therapeutics and CytoSorbents, saw their stock prices increase, often coinciding with recent Q2 earnings reports. Conversely, stocks like Edap TMS and …
Search by ticker symbol or company name and select a result to open its chart.